Shanghai-based cancer drug developer Ascentage Pharma Group Corporation has raised US$15.5 million in a new funding round led by Oriza Capital and YuanMing Capital, according to media reports. Ascentage Pharma span off from Ascenta Therapeutics, Inc. in 2009. In January 2015, Chinese biotechnology 3SBio Inc. invested US$3 million in the company to help its research […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.